The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 10, 2016

Filed:

Sep. 20, 2011
Applicants:

Paul S. Hoffman, Charlottesville, VA (US);

Timothy L. Macdonald, Charlottesville, VA (US);

Eric R. Houpt, Keswick, VA (US);

Thomas E. Ballard, Jr., Middletown, CT (US);

Inventors:

Paul S. Hoffman, Charlottesville, VA (US);

Timothy L. MacDonald, Charlottesville, VA (US);

Eric R. Houpt, Keswick, VA (US);

Thomas E. Ballard, Jr., Middletown, CT (US);

Assignee:

UNIVERSITY OF VIRGINIA PATENT FOUNDATION, Charlottesville, VA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/381 (2006.01); A61P 31/04 (2006.01); A61P 31/06 (2006.01); A61K 31/426 (2006.01); A61K 31/427 (2006.01);
U.S. Cl.
CPC ...
A61K 31/381 (2013.01); A61K 31/426 (2013.01); A61K 31/427 (2013.01);
Abstract

The invention provides for the use of antimicrobial chemical entities based on a nitrothiazolide backbone that exhibit anti-mycobacteria activity, including thecausing tuberculosis. Multiple compounds were synthesized and screened for anti-tuberculosis activity. Disclosed herein are a series of compounds with anti-tuberculosis activity, including six leads that completely inhibited bacterial growth at 5 micrograms per ml or less. Three of these compounds were tested to determine MIC and these ranged between 1 and 4 micrograms per ml against both drug susceptiblestrains and strains that are multi-drug resistant (MDR) including XDR strains. The compounds developed are derived from parent compound nitazoxanide, which had no inhibitory activity in the stringent testing format used herein. The derivatives were synthesized using a di-nitro-thiophene or 4-Chloro-5-Nitro-thiazole scaffold and R groups connected via a peptide bond (NHCO) to cyclic compounds such as benzene, thiophene or furans. Many of these compounds have broad spectrum activity against Gram positive bacteria including(MRSA) and. Several of these lead compounds were not toxic for mice at 200 mg/Kg doses administered over a period of three days.


Find Patent Forward Citations

Loading…